Related Experiment Videos
In vitro brodimoprim activity on bacterial strains
C Benoit-Lemercier1, E Bergogne-Bérézin, M L Joly-Guillou
1Department of Microbiology, Bichat-Claude Bernard University-Hospital, Paris, France.
Journal of Chemotherapy (Florence, Italy)
|December 1, 1993
Summary
Brodimoprim (BDP) demonstrates antibacterial and bactericidal efficacy comparable to trimethoprim (TMP) against respiratory pathogens. BDP shows superior activity against resistant staphylococci and enterococci.
Area of Science:
- Microbiology
- Pharmacology
Background:
- Antibiotic resistance is a growing concern in respiratory tract infections.
- Novel antibacterial agents are needed to combat resistant pathogens.
Purpose of the Study:
- To evaluate the in vitro antibacterial activity of brodimoprim (BDP) compared to trimethoprim (TMP) and other antibiotics.
- To assess BDP's bactericidal kinetics and its correlation with agar diffusion tests.
Main Methods:
- Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) were determined for 237 bacterial strains.
- Bactericidal kinetics and regression analysis between MICs and inhibition zones for BDP were performed.
Main Results:
- BDP exhibited in vitro activity similar to TMP against tested respiratory pathogens.
- Low MICs were observed for BDP against key pathogens including Haemophilus influenzae and Staphylococcus aureus (methicillin-resistant).
- BDP demonstrated potent bactericidal activity, achieving a 4-log decrease in viable cells within 7 hours for susceptible strains.
Conclusions:
- Brodimoprim possesses significant in vitro antibacterial and bactericidal properties against common respiratory pathogens.
- BDP is a promising alternative, particularly for infections caused by methicillin-resistant staphylococci and enterococci.